Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1 14Phase 3 8Phase 1/2 4Phase NA 1Phase EARLY_PHASE1 1

Status

Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Lymphoma, Large B-Cell, Diffuse 22Breast Neoplasms 19Lymphoma 14Sarcoma 13Lymphoma, Non-Hodgkin 9Lymphoma, Follicular 8Lymphoma, B-Cell 8Hodgkin Disease 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Mantle-Cell 5Immunoblastic Lymphadenopathy 5Ovarian Neoplasms 4Neoplasms 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Large-Cell, Anaplastic 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Hepatocellular 4Recurrence 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Primary Effusion 3Chondrosarcoma 3Triple Negative Breast Neoplasms 2Solitary Fibrous Tumors 2Sarcoma, Clear Cell 2Plasmablastic Lymphoma 2Osteosarcoma 2Lymphoma, T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Liver Neoplasms 2

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × Doxorubicin × Clear all
NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Eisai Inc.

Phase 1/2 Active not recruiting
301 enrolled
GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05201248 2025-01-07

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

Genmab

Phase 1/2 Active not recruiting
49 enrolled
Lymphoid

Neoplasms, Lymphoma, B-Cell

NCT02261805 2018-04-23

A Phase I/II Study of Ganetespib in Combination With Doxorubicin

Georgetown University

Phase 1/2 Terminated
11 enrolled 7 charts
Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT00124956 2017-09-11

Doxorubicin Pharmacokinetic (PK) Study

Boston Children's Hospital

Phase 1/2 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡